Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Therapy Initiation

Score: 71/100 | MI:10 TR:6 N:8 DI:9 RE:7 CE:6 TE:8 EB:9 AU:6 TP:5

Experiment Overview

This study aims to identify the optimal timing for initiating disease-modifying therapies in presymptomatic GRN mutation carriers. Using longitudinal biomarker tracking, we will develop a disease staging system that guides intervention timing to maximize therapeutic benefit before irreversible neuronal damage occurs.

Hypothesis

Score: 71/100 | MI:10 TR:6 N:8 DI:9 RE:7 CE:6 TE:8 EB:9 AU:6 TP:5

Experiment Overview

This study aims to identify the optimal timing for initiating disease-modifying therapies in presymptomatic GRN mutation carriers. Using longitudinal biomarker tracking, we will develop a disease staging system that guides intervention timing to maximize therapeutic benefit before irreversible neuronal damage occurs.

Hypothesis

Presymptomatic GRN carriers progress through identifiable biomarker stages:

Optimal intervention window is Stage 1-2, before significant TDP-43 pathology and neuronal loss.

Research Gap Addressed

FTD Gap #8: What is the optimal timing for intervention in presymptomatic GRN carriers?

Validation Protocol

Phase 1: Biomarker Signature Discovery

Approach: Establish biomarkers that track disease progression in GRN carriers

Cohort:

• 100 presymptomatic GRN mutation carriers (ages 30-70)
• 50 at-risk family members (non-carriers as controls)
• Annual assessment for 5 years

Phase 2: Staging System Validation

Approach: Validate biomarker-based staging in independent cohort

Cohort:

• 50 new presymptomatic carriers
• Apply staging algorithm
• Track progression over 3 years

Phase 3: Intervention Window Testing

Approach: Determine if earlier intervention provides better outcomes

Trial Design:

• Enroll Stage 1-2 carriers for progranulin replacement therapy (AAV-GRN)
• Compare outcomes by baseline stage
• Primary endpoint: biomarker normalization at 2 years

• Clinical progression rate
• MRI atrophy rate
• NfL trajectory

Expected Outcomes

Timeline

| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 60 months | Biomarker signatures established |
| Phase 2 | 36 months | Staging system validated |
| Phase 3 | 48 months | Intervention window defined |

Total: 10 years to definitive timing guidance

Feasibility Assessment

| Factor | Score | Notes |
|--------|-------|-------|
| Technical Feasibility | 7/10 | Biomarkers established; requires longitudinal commitment |
| Recruitment Feasibility | 8/10 | GRN families identifiable; international collaboration needed |
| Timeline | 10 years | Long but necessary for presymptomatic studies |
| Cost | $8.5M | Major costs: longitudinal assessments, personnel |

Cost Breakdown:

• Phase 1: $3.5M (100 carriers × 5 years × $7K/year)
• Phase 2: $2.0M (50 carriers × 3 years × $13K/year)
• Phase 3: $3.0M (intervention trial)

Clinical Impact

• Current problem: No guidance on when to treat presymptomatic carriers
• Solution: Biomarker-driven staging guides intervention timing
• Benefit: Maximize therapeutic benefit, prevent irreversible damage
• Broader application: Template for other genetic FTD forms (MAPT, C9orf72)

Cross-Disease Value

• Model for presymptomatic intervention in other neurodegenerative diseases
• Biomarker staging applicable to AD (preclinical), PD (prodromal)
• Progranulin biology relevant to ALS and other TDP-43opathies

See Also

• [GRN Carrier Resilience](/experiments/grn-carrier-resilience-ftd)](/experiments)
• [Progranulin Replacement Therapy](/experiments/progranulin-replacement-therapy-ftd)](/experiments)
• [FTD Knowledge Gaps](/gaps/ftd)](/gaps)
• [FTD Biomarkers](/diagnostics/ftd-biomarkers)

References